Download - 0014Clinical Pharmacology Notes 2015
-
8/18/2019 0014Clinical Pharmacology Notes 2015
1/84
Pharmacokinetics:MetabolismDrug metabolism usually involves two types of biochemical reactions - phase I and phase II
reactions
Phase I reactions:
• Oxidation, reduction, hydrolysis.
• Mainly performed by the P450 enzymes but some drugs are metabolised by specific
enzymes, for example alcohol dehydrogenase and xanthine oxidase.
• Products of phase I reactions are typically more active and potentially toxic
phase II reactions:
• Conjugation.
• Products are typically inactive and excreted in urine or bile.• Glucuronyl, acetyl, methyl, sulphate and other groups are typically involved
The majority of phase I and phase II reactions take place in the liver
First-pass metabolism
• This is a phenomenon where the concentration of a drug is greatly reduced before it
reaches the systemic circulation due to hepatic metabolism.• As a consequence much larger doses are need orally than if given by other routes.
• This effect is seen in many drugs, including:
1)aspirin
2)isosorbide dinitrate
3)glyceryl trinitrate
4)lignocaine
5)propranolol
6)verapamil
7)isoprenaline
8)testosterone
9)hydrocortisone
Questions concerning zero-order kinetics and acetylator status are also common in the exam
Zero-order kinetics
• Zero-order kinetics describes metabolism which is independent of the concentration of thereactant.
1
-
8/18/2019 0014Clinical Pharmacology Notes 2015
2/84
-
8/18/2019 0014Clinical Pharmacology Notes 2015
3/84
4)amiodarone
5)allopurinol
6)imidazoles: ketoconazole, fluconazole
7)SSRIs: fluoxetine, sertraline
8)ritonavir
9)sodium valproate
10) acute alcohol intake
11) quinupristin
P450 drug interactions: more detailWhilst you are expected to know in broad terms what are the main inhibitors and inducers of
the P450 system it is unlikely that you will be asked detailed questions about the individual
enzyme systems.
It is worthwhile noting that the most important and common reason for drug interactions is the
P450CYP3A4 system.
The table below shows the main enzyme systems that are affected by common drugs. There
is clearly a lot of overlap within the various P450 enzymes.
P450system Substrates Inhibitors Inducers
CYP3A4 MacrolidesAntiretroviralsCalcium channel
blockers
MacrolidesProtease inhibitors(including ritonavir)Imidazoles
CarbamazepinePhenytoinPhenobarbitoneRifampicint !ohn"s #ort
CYP2D6 $ricyclicantidepressants
RIsRitonavir
3
-
8/18/2019 0014Clinical Pharmacology Notes 2015
4/84
P450system Substrates Inhibitors Inducers
Antipsychotics
CYP2C9 #arfarinulfonylureas
ImidazolesAmiodarone
odium valproate
Rifampicin
CYP1A2 $heophylline Ciproflo%acin moking&meprazole
CYP21 Alcohol ChronicalcoholIsoniazid
!"#$ %&'(
!"#$%&$ '()'*
#*+,- ./ + + 7,8,$! :!;+* ?@$! B8) E(Q) XRQ) KW$!% &$;,$!
+,- ./0123 4-56 ,7849: 49; :5-?@,/B,-D=EFG/H59: GJ6K1L+,$!
FG019: N,* OQ G-,0 S93 .T; S7@ UL V40 WTXQ 4YZ; [/1\19: >:,]^: G01_ S93 :5`Q B:
4
http://void%280%29/http://www.aljazeera.net/home/getpage/f2543b4a-bc1a-44bb-9be3-0cdcb2096083/0b5251c2-e1f2-44a5-a8fc-ee1ccf0093bchttp://www.aljazeera.net/home/getpage/f2543b4a-bc1a-44bb-9be3-0cdcb2096083/0b5251c2-e1f2-44a5-a8fc-ee1ccf0093bchttp://void%280%29/
-
8/18/2019 0014Clinical Pharmacology Notes 2015
5/84
279: -579: .9: ] (>1959:) W9: OQ 6 4Y1L j,9: 6 B; :,]^: G019 G/B1959: G7`9: [1q
F519 1Q \9: 4q 50 >,/B195L G1JXQ V:3 O1L :,0 >8 18
FG//:523 G859 L GYX1L w: /L G/] S0 U718K1L G919:; GB/x9L GQ,`K9: QUZL >1959: 6 5U7*:6 GT]; G9;49: q: WUB Q 6 \9: {Q [Q 4-49: 8 18 |X/2 F}/9: +5*; V?/9:;
4-49L +4YZ 18 W9: OQ 6 ~,_; ] >/L; G@3 W •€ G\1]; L:,72: [/\1] [Q 58‚L Q4YZ 9 .2 ƒ ; F[/B:,Y9: -Q [Q
V,„ 6 ./0123 4-56 '* 8; 5-X- .H [\9: .]: F•19: G-UB 6 G\9:
arid Ismaif
ghe date and face o birth" !une
-
8/18/2019 0014Clinical Pharmacology Notes 2015
6/84
—e succeeded in –inning a seat in Parliament during the ninth legislative term from
-
8/18/2019 0014Clinical Pharmacology Notes 2015
7/84
• Whilst it is common that non-hypoxic patients receive oxygen therapy there is little
evidence to support this approach.
• The 2008 British Thoracic Society oxygen therapy guidelines advise not giving oxygen
unless the patient is hypoxic.
B)Antithrombin treatment:
• Fondaparinux should be offered to patients who are not at a high risk of bleeding and
who are not having angiography within the next 24 hours.
• If angiography is likely within 24 hours or a patient’s creatinine is > 265umol/l
unfractionated heparin should be given.
C)Clopidogrel 300mg should be given toall patients and continued for 12 months.
D)Intravenous glycoprotein IIb/IIIa receptor antagonists
• Eptifibatide or tirofiban
• It should be given to:
1)Patients who have an intermediate or higher risk of adverse cardiovascular events(predicted 6-month mortality above 3.0%), and
2)Who are scheduled to undergo angiography within 96 hours of hospital admission
E)Coronary angiography:
• Should be considered within 96 hours of first admission to hospital to patients who
have a predicted 6-month mortality above 3.0%.
• It should also be performed as soon as possible in patients who are clinically unstable.
Mechanism of action of drugs commonly used in the management of acute coronary syndrome:
ledication lechanism o action
Asirin Antiplatelet inhibits the production of thrombo%ane A<
Cfoidoref Antiplatelet inhibits A™P binding to its platelet receptor
noaarin Activates antithrombin III’ –hich in turn potentiates the inhibition of coagulationfactors œa
ondaarinu Activates antithrombin III’ –hich in turn potentiates the inhibition of coagulation
factors œaipafirudin Reversible direct thrombin inhibitor
)sirin• Aspirin works by blocking the action of both cyclooxygenase-1 and 2.
• Cyclooxygenase is responsible for prostaglandin, prostacyclin and thromboxane synthesis.
• The blocking of thromboxane A2 formation in platelets reduces the ability of platelets to
aggregate which has lead to the widespread use of low-dose aspirin in cardiovascular
disease.
-
8/18/2019 0014Clinical Pharmacology Notes 2015
8/84
• Until recent guidelines changed all patients with established cardiovascular disease took
aspirin if there was no contraindication. Following the 2010 technology appraisal of
clopidogrel this is no longer the case*.
• Two recent trials (the Aspirin for Asymptomatic Atherosclerosis and the Antithrombotic
Trialists Collaboration) have cast doubt on the use of aspirin in primary prevention of
cardiovascular disease.• Guidelines have not yet changed to reflect this. However the Medicines and Healthcare
products Regulatory Agency (MHRA) issued a drug safety update in January 2010
reminding prescribers that aspirin is not licensed for primary prevention.
What do the current guidelines recommend?
• first-line for patients with ischaemic heart disease
Potentiates
• oral hypoglycaemics
• warfarin
• steroids
*NICE now recommend clopidogrel first-line following an ischaemic stroke and for peripheral
arterial disease. For TIAs the situation is more complex. Recent Royal College of Physician
(RCP) guidelines support the use of clopidogrel in TIAs. However the older NICE guidelines
still recommend aspirin + dipyridamole - a position the RCP state is 'illogical'
iyridamole• Dipyridamole is an antiplatelet mainly used in combination with aspirin after an ischaemic
stroke or transient ischaemic attack.
Mechanism of action:
• inhibits phosphodiesterase, elevating platelet cAMP levels which in turn reduce
intracellular calcium levels
• other actions include reducing cellular uptake of adenosine and inhibition of
thromboxane synthase
-
8/18/2019 0014Clinical Pharmacology Notes 2015
9/84
Familial Hypercholesterolaemia
• FH is an autosomal dominant condition that is thought to affect around 1 in 500 people.
• It results in high levels of LDL-cholesterol which, if untreated, may cause early cardiovascular
disease (CVD).• FH is caused by mutations in the gene which encodes the LDL-receptor protein.
Clinical diagnosis is now based on theSimon Broome criteria
The Simon Broome criteria:
1)in adults total cholesterol (TC) > 7.5 mmol/l and LDL-C > 4.9 mmol/l or
Children TC > 6.7 mmol/l and LDL-C > 4.0 mmol/l,
plus:
1)For definite FH:
• tendon xanthoma in patients or
• 1st or 2nd degree relatives or
• DNA-based evidence of FH
2)For possible FH:family history of myocardial infarction:
• below age 50 years in 2nd degree relative,
• below age 60 in 1st degree relative, or
• a family history of raised cholesterol levels
Management
• the use of CVD risk estimation using standard tables is not appropriate in FH as they do not
accurately reflect the risk of CVD
• referral to a specialist lipid clinic is usually required
the maximum dose of potent statins are usually required
• First-degree relatives have a 50% chance of having the disorder and should therefore be
offered screening. This includes children who should be screened by the age of 10 years if
there is one affected parent
• statins should be discontinued in women 3 months before conceptiondue to the risk
of congenital defects
yerliidaemia: mechanism o* action and ad6ersee7ects
The following table compares the side-effects of drugs used in hyperlipidaemia:
8
-
8/18/2019 0014Clinical Pharmacology Notes 2015
10/84
Drus lechanism o action Adperse eects
tatins —M˜ CoA reductase inhibitors Myositis’ deranged $s
“zetimibe ™ecreases cholesterol absorption in the small intestine —eadache
šicotinic acid ™ecreases hepatic ž™ secretion lushing’ myositis
ibrates Agonist of PPARalpha therefore increases lipoproteinlipase e%pression
Myositis’ pruritus’cholestasis
Cholestyramine
™ecreases bile acid reabsorption in the small intestine’upregulating the amount of cholesterol that isconverted to bile acid
˜I sideeffects
,tatinsStatins inhibit the action of HMG-CoA reductase, the rate-limiting enzyme in hepatic
cholesterol synthesis
Adverse effects:
1) Myopathy:
• Includes myalgia, myositis, rhabdomyolysis and asymptomatic raised creatine
kinase.
•
Risks factors for myopathy include advanced age, female sex, low body massindex and presence of multisystem disease such as diabetes mellitus.
• Myopathy is more common in lipophilic statins (simvastatin, atorvastatin) than
relatively hydrophilic statins (rosuvastatin, pravastatin, fluvastatin)
2) Liver impairment:
• The 2014 NICE guidelines recommend checking LFTs at baseline, 3 months
and 12 months.
• Treatment should be discontinued if serum transaminase concentrations rise to
and persist at 3 times the upper limit of the reference range
3)There is some evidence that statins mayincrease the risk of intracerebral
haemorrhage in patients who've previously had a stroke. This effect is not seen in
primary prevention. For this reason the Royal College of Physicians recommend
avoiding statins in patients with a history of intracerebral haemorrhage
Who should receive a statin?
10
-
8/18/2019 0014Clinical Pharmacology Notes 2015
11/84
-
8/18/2019 0014Clinical Pharmacology Notes 2015
12/84
eart *ailure:rug managementA number of drugs have been shown to improve mortality in patients with chronic heart
failure:
1)ACE inhibitors (SAVE, SOLVD, CONSENSUS)
2)spironolactone (RALES)
3)beta-blockers (CIBIS)4)hydralazine with nitrates (VHEFT-1)
No long-term reduction in mortality has been demonstrated for loop diuretics such as
furosemide.
NICE issued updated guidelines on management in 2010, key points include:
1)first-line treatment for all patients is both an ACE-inhibitor and a beta-blocker2)second-line treatment is now either an aldosterone antagonist, angiotensin II receptor
blocker or a hydralazine in combination with a nitrate
12
-
8/18/2019 0014Clinical Pharmacology Notes 2015
13/84
3)if symptoms persist cardiac resynchronisation therapy or digoxin* should be considered
4)diuretics should be given for fluid overload
5)offer annual influenza vaccine
6)offer one-off** pneumococcal vaccine
*digoxin has also not been proven to reduce mortality in patients with heart failure. It may
however improve symptoms due to its inotropic properties. Digoxin is strongly indicated if
there is coexistent atrial fibrillation
**adults usually require just one dose but those with asplenia, splenic dysfunction or chronic
kidney disease need a booster every 5 years
igo9in and digo9in to9icity• Digoxin is a cardiac glycoside now mainly used for rate control in the management of atrial
fibrillation.
• As it has positive inotropic properties it is sometimes used for improving symptoms (but
not mortality) in patients with heart failure.
Mechanism of action:
1)decreases conduction through the atrioventricular node which slows the ventricular rate
in atrial fibrillation and flutter
2)Increases the force of cardiac muscle contraction due to inhibition of the Na+ /K+ATPase
pump.
3)Also stimulates vagus nerve
Digoxin toxicity
• Plasma concentration alone does not determine whether a patient has developed digoxin
toxicity.
• The BNF advises that the likelihood of toxicity increases progressively from 1.5 to 3 mcg/l.
Features:
1)generally unwell, lethargy, nausea & vomiting, anorexia, confusion, yellow-green vision
13
-
8/18/2019 0014Clinical Pharmacology Notes 2015
14/84
2)arrhythmias (e.g. AV block, bradycardia)
Precipitating factors:
1)classically: hypokalaemia*
2)increasing age
3)renal failure
4)myocardial ischaemia
5)hypomagnesaemia,
6)hypercalcaemia, hypernatraemia, acidosis
7)hypoalbuminaemia
8)hypothermia
9)hypothyroidism
10) Drugs: amiodarone, quinidine, verapamil, diltiazem, spironolactone (competesfor secretion in distal convoluted tubule therefore reduce excretion), ciclosporin. Also
drugs which cause hypokalaemia e.g. thiazides and loop diuretics
Management:
1)Digibind
2)correct arrhythmias
3)monitor potassium
*hyperkalaemia may also worsen digoxin toxicity, although this is very small print
Prescribing in atients ith heart *ailureThe following medications may exacerbate heart failure:
1)thiazolidinediones*: pioglitazone is contraindicated as it causes fluid retention
2)verapamil: negative inotropic effect
3)NSAIDs**/glucocorticoids: should be used with caution as they cause fluid retention
4)class I antiarrhythmics; flecainide (negative inotropic and proarrhythmic effect)
*pioglitazone is now the only thiazolidinedione on the market
**low-dose aspirin is an exception - many patients will have coexistent cardiovascular disease
and the benefits of taking aspirin easily outweigh the risks
14
-
8/18/2019 0014Clinical Pharmacology Notes 2015
15/84
;endro
-
8/18/2019 0014Clinical Pharmacology Notes 2015
16/84
Adverse effects:
1)hypotension
2)hyponatraemia
3)hypokalaemia
4)hypochloraemic alkalosis
5)ototoxicity
6)hypocalcaemia
7)renal impairment (from dehydration + direct toxic effect)
8)hyperglycaemia (less common than with thiazides)
9)gout
;eta>blocker o6erdoseFeatures:
• bradycardia
• hypotension
• heart failure
• syncope
Management:
• if bradycardic then atropine• in resistant cases glucagon may be used
Haemodialysis is not effective in beta-blocker overdose
?alcium channel blockers• Calcium channel blockers are primarily used in the management of cardiovascular
disease.• Voltage-gated calcium channels are present in:
1)myocardial cells,
2)cells of the conduction system
3)the vascular smooth muscle cells
The various types of calcium channel blockers have varying effects on these three areas and
it is therefore important to differentiate their uses and actions.
1
-
8/18/2019 0014Clinical Pharmacology Notes 2015
17/84
amfes Indications notes Sideeects and cautions
veraamif ) Angina’ hypertension’ arrhythmias• —ighly negatively inotropic• hould not be given –ith betablockers as
may cause heart block • hould not be given in ventricular
tachcardia
) —eart failure’
-
8/18/2019 0014Clinical Pharmacology Notes 2015
18/84
Cfass amfes lechanism o action xotes
Atenolol”isoprololMetoprolol
antagonists
III AmiodaroneotalolIbutilide”retylium
”lock potassium channels
Iž žerapamil™iltiazem
Calcium channel blockers
1
-
8/18/2019 0014Clinical Pharmacology Notes 2015
19/84
-
8/18/2019 0014Clinical Pharmacology Notes 2015
20/84
Clecainide• Flecainide is a Vaughan Williams class 1c antiarrhythmic.
• It slows conduction of the action potential by acting as a potent sodium channel blocker.
• This may be reflected by widening of the QRS complex and prolongation of the PR interval
• The Cardiac Arrhythmia Suppression Trial (CAST, 1989) investigated the use of agents to
treat asymptomatic or mildly symptomatic premature ventricular complexes (PVCs) post
myocardial infarction. The hypothesis was that this would reduce deaths from ventricular
arrhythmias.Flecainide was actually shown to increase mortality post myocardial
infarction and is therefore contraindicated in this situation
Indications:
• atrial fibrillation
• SVT associated with accessory pathway e.g. Wolf-Parkinson-White syndrome
Adverse effects
1)negatively inotropic
2)bradycardia
3)proarrhythmic
4)oral paraesthesia5)visual disturbances
20
-
8/18/2019 0014Clinical Pharmacology Notes 2015
21/84
-
8/18/2019 0014Clinical Pharmacology Notes 2015
22/84
AIg tye 1 AIg tye 2
Pathophysiology
“%cess iodineinduced thyroidhormone synthesis
Amiodaronerelated destructivethyroiditis
˜oitre Present Absent
Management Carbimazole or potassium perchlorate Corticosteroids
Unlike in AIH, amiodarone should be stopped if possible in patients who develop AIT
)denosine
The effects of adenosine are:⇒ Enhanced by dipyridamole (anti-platelet agent) and
⇒ blocked by theophyllines
• It should be avoided in asthmatics due to possible bronchospasm.
Mechanism of action:
1)causes transient heart block in the AV node
2)agonist of the A1 receptor which inhibits adenylyl cyclase thus reducing cAMP and
causing hyperpolarization by increasing outward potassium flux
3)adenosine has a very short half-life of about 8-10 seconds
Adverse effects:
1)chest pain
2)bronchospasm
3)can enhance conduction down accessory pathways, resulting in increased ventricular
rate (e.g. WPW syndrome)
22
-
8/18/2019 0014Clinical Pharmacology Notes 2015
23/84
)drenalineAdrenaline is a sympathomimetic amine with both alpha and beta adrenergic stimulating
properties
Indications:
• anaphylaxis
• cardiac arrest
Recommend Adult Life Support (ALS) adrenaline doses:
1)anaphylaxis: 0.5ml 1:1,000 IM
2)cardiac arrest:
⇒ 1ml of 1:1000 IV
⇒ 10ml 1:10,000 IV
Management of accidental injection:
• local infiltration of phentolamine
)drenocetor antagonistsAlpha antagonists
• alpha-1: doxazosin
• alpha-1a: tamsulosin - acts mainly on urogenital tract
• alpha-2: yohimbine
• non-selective: phenoxybenzamine (previously used in peripheral arterial disease)
23
-
8/18/2019 0014Clinical Pharmacology Notes 2015
24/84
-
8/18/2019 0014Clinical Pharmacology Notes 2015
25/84
⇒ the British Society for Rheumatology recommend 'In uncomplicated gout uric
acid lowering drug therapy should be started if a second attack, or further
attacks occur within 1 year'
2)tophi
3)renal disease
4)uric acid renal stones
5)prophylaxis if on cytotoxics or diuretics
*patients with Lesch-Nyhan syndrome often take allopurinol for life
Interactions
1)Azathioprine:
•
Azathioprine metabolised to active compound 6-mercaptopurine• xanthine oxidase is responsible for the oxidation of 6-mercaptopurine to 6-thiouric acid
• allopurinol can therefore lead to high levels of 6-mercaptopurine
• a much reduced dose (e.g. 25%) must therefore be used if the combination cannot be
avoided
2) Cyclophosphamide
• allopurinol reduces renal clearance, therefore may cause marrow toxicity
)ntihistamines• Antihistamines (H1 inhibitors) are of value in the treatment of allergic rhinitis and urticaria.
Examples of sedating antihistamines:
• chlorpheniramine
25
-
8/18/2019 0014Clinical Pharmacology Notes 2015
26/84
• As well as being sedating these antihistamines have some antimuscarinic properties
(e.g. urinary retention, dry mouth).
Examples of non-sedating antihistamines
• loratidine
• cetirizine
Of the non-sedating antihistamines there is some evidence that cetirizine may cause more
drowsiness than other drugs in the class.
rugs hich act on serotonin recetors• Below is a summary of drugs which are known to act via modulation of the serotonin (5-
HT) system.
• It should be noted that 5-HT receptor agonists are used in the acute treatment of migrainewhilst 5-HT receptor antagonists are used in prophylaxis
Agonists:
• sumatriptan is a 5-HT1D receptor agonist which is used in the acute treatment of
migraine
• ergotamine is a partial agonist of 5-HT1 receptors
Antagonists:
• Pizotifen is a 5-HT2 receptor antagonist used in the prophylaxis of migraine attacks.
• Methysergide is another antagonist of the 5-HT2 receptor but is rarely used due to the
risk ofretroperitoneal fibrosis
• cyproheptadine is a 5-HT2 receptor antagonist which is used tocontrol diarrhoea in
patients with carcinoid syndrome
• ondansetron is a 5-HT3 receptor antagonist and is used as an antiemetic
5>-3 antagonists• 5-HT3 antagonists are antiemetics used mainly in the management of chemotherapy
related nausea.
• They mainly act in the chemoreceptor trigger zone area of the medulla oblongata.
Examples:
• ondansetron• granisetron
Adverse effects:
2
-
8/18/2019 0014Clinical Pharmacology Notes 2015
27/84
• constipation is common
Motion sickness• Motion sickness describes the nausea and vomiting which occurs when an apparent
discrepancy exists between visually perceived movement and the vestibular systems
sense of movement
Management:
1)The BNF recommends hyoscine (e.g. transdermal patch) as being the most effective
treatment. Use is limited due to side-effects
2)non-sedating antihistamines such as cyclizine or cinnarizine are recommended in
preference to sedating preparation such as promethazine
Proton um inhibitors• Proton pump inhibitors (PPI) are a group of drugs which profoundly reduce acid secretion
in the stomach.
• They irreversibly blocking the hydrogen/potassium adenosine triphosphatase enzyme
system (the H+/K+ ATPase) of the gastric parietal cell
• Examples include omeprazole and lansoprazole
2
-
8/18/2019 0014Clinical Pharmacology Notes 2015
28/84
,teroid dosesEquivalence
• 1mg prednisolone = 4mg hydrocortisone
• 1mg dexamethasone = 7mg prednisolone = 28 mg hydrocortisone
)zathiorine• Azathioprine is metabolised to the active compound mercaptopurine, a purine analogue
that inhibits purine synthesis.
• A thiopurine methyltransferase (TPMT) test may be needed to look for individuals prone to
azathioprine toxicity.
• A significant interaction may occur with allopurinol and hence lower doses of azathioprine
should be used.
Adverse effects include:
1)bone marrow depression
2)nausea/vomiting
3)pancreatitis
?iclosorin• Ciclosporin is an immunosuppressant which decreases clonal proliferation of T cells by
reducing IL-2 release.
• It acts by binding to cyclophilin forming a complex which inhibits calcineurin, a
phosphotase that activates various transcription factors in T cells
Adverse effects: (note how everything is increased - fluid, BP, K+, hair, gums, glucose)
1)nephrotoxicity
2)hepatotoxicity
3)fluid retention4)hypertension
5)hyperkalaemia
2
-
8/18/2019 0014Clinical Pharmacology Notes 2015
29/84
6)hypertrichosis
7)gingival hyperplasia
8)tremor
9)impaired glucose tolerance
10) hyperlipidaemia
11) increased susceptibility to severe infection
Interestingly for an immunosuppressant, ciclosporin is noted by the BNF to be 'virtually non-
myelotoxic'.
Indications:
1)following organ transplantation
2)rheumatoid arthritis
3)psoriasis (has a direct effect on keratinocytes as well as modulating T cell function)4)ulcerative colitis
5)pure red cell aplasia
-acrolimus• Tacrolimus is a macrolide used as an immunosuppressant to prevent transplant rejection.
• It has a very similar action to ciclosporin
• The action of tacrolimus differs in that it binds to a protein called FKBP rather than
cyclophilin
• Tacrolimus is more potent than ciclosporin and hence the incidence of organ rejection is
less. However, nephrotoxicity and impaired glucose tolerance is more common
28
-
8/18/2019 0014Clinical Pharmacology Notes 2015
30/84
oamine recetor agonists• e.g.bromocriptine, ropinirole, cabergoline, apomorphine
•
Ergot-derived dopamine receptor agonists (bromocriptine, cabergoline, pergolide*) havebeen associated with pulmonary, retroperitoneal and cardiac fibrosis.
• The Committee on Safety of Medicines advice that an ESR, creatinine and chest x-ray
should be obtained prior to treatment and patients should be closely monitored
Indications:
1)Parkinson's disease
2)prolactinoma/galactorrhoea
3)cyclical breast disease
4)acromegaly
Currently accepted practice in the management of patients with Parkinson's disease is to
delay treatment until the onset of disabling symptoms and then to introduce a dopamine
receptor agonist. If the patient is elderly, L-dopa is sometimes used as an initial treatment
Adverse effects:
1)nausea/vomiting
30
-
8/18/2019 0014Clinical Pharmacology Notes 2015
31/84
2)postural hypotension
3)hallucinations
4)daytime somnolence
*pergolide was withdrawn from the US market in March 2007 due to concern regarding
increased incidence of valvular dysfunction
EctreotideOverview
• long-acting analogue of somatostatin
• somatostatin is released from D cells of pancreas and inhibits the release of growth
hormone, glucagon and insulin
Uses:
1)acute treatment of variceal haemorrhage
2)acromegaly
3)carcinoid syndrome
4)prevent complications following pancreatic surgery
5)VIPomas
6)refractory diarrhoea
Adverse effects:
• gallstones (secondary to biliary stasis)
Monoamine o9idase inhibitors• serotonin and noradrenaline are metabolised by monoamine oxidase in the presynaptic
cell
Non-selective monoamine oxidase inhibitors
• e.g. tranylcypromine, phenelzine
• used in the treatment of atypical depression (e.g. hyperphagia) and other psychiatric
disorder
• not used frequently due to side-effects
Adverse effects of non-selective monoamine oxidase inhibitors:
• hypertensive reactions with tyramine containing foods
31
-
8/18/2019 0014Clinical Pharmacology Notes 2015
32/84
e.g. cheese, pickled herring,GB59: Bovril, Oxo, Marmite, broad beans
• anticholinergic effects
-ricyclic o6erdose• Overdose of tricyclic antidepressants is a common presentation to emergency
departments
• Amitriptyline and dosulepin (dothiepin) are particularly dangerous in overdose.
Early features relate to anticholinergic properties:
1)dry mouth,
32
-
8/18/2019 0014Clinical Pharmacology Notes 2015
33/84
2)dilated pupils,
3)agitation,
4)sinus tachycardia,
5)blurred vision
Features of severe poisoning include:
1)arrhythmias
2)seizures
3)metabolic acidosis
4)coma
ECG changes include:
1)sinus tachycardia
2)widening of QRS
3)prolongation of QT interval
Widening of QRS > 100ms is associated with an increased risk of seizures
whilst QRS > 160ms is associated with ventricular arrhythmias
Management:
1)IV bicarbonate may reduce the risk of seizures and arrhythmias in severe toxicity
2)arrhythmias:
⇒ Response to lignocaine is variable and it should be emphasized that correction of
acidosis is the first line in management of tricyclic induced arrhythmias
⇒ Class 1a (e.g. Quinidine) and class Ic antiarrhythmics (e.g. Flecainide) are
contraindicated as they prolong depolarisation.
⇒ Class III drugs such as amiodarone should also be avoided as they prolong the QT
interval.3)intravenous lipid emulsion is increasingly used to bind free drug and reduce toxicity
4)dialysis is ineffective in removing tricyclics
33
-
8/18/2019 0014Clinical Pharmacology Notes 2015
34/84
,t FohnGs AortOverview
• shown to be as effective as tricyclic antidepressants in the treatment of mild-moderate
depression
• mechanism: thought to be similar to SSRIs (although noradrenaline uptake inhibition has
also been demonstrated)
• NICE advise 'may be of benefit in mild or moderate depression, but its use should not be
prescribed or advised because of uncertainty about appropriate doses, variation in the
nature of preparations, and potential serious interactions with other drugs'
Adverse effects:
1)profile in trials similar to placebo
2)can cause serotonin syndrome
3)Inducer of P450 system, therefore:
⇒ Decreased levels of drugs such as warfarin, ciclosporin.
⇒ The effectiveness of the combined oral contraceptive pill may also be reduced
34
-
8/18/2019 0014Clinical Pharmacology Notes 2015
35/84
-
8/18/2019 0014Clinical Pharmacology Notes 2015
36/84
Eculogyric crisisAn oculogyric crisis is a dystonic reaction to certain drugs or medical conditions
Features:
• restlessness, agitation
• involuntary upward deviation of the eyes
Causes:
1)phenothiazines
2)haloperidol
3)metoclopramide
4)postencephalitic Parkinson's disease
Management:
• procyclidine
Eioid misuse• Opioids are substances which bind to opioid receptors.
• This includes both naturally occurring opiates such as morphine and synthetic opioids
such as buprenorphine and methadone.
Features of opioid misuse:
1)rhinorrhoea
2)needle track marks
3)pinpoint pupils
4)drowsiness
5)watering eyes
6)yawning
Complications of opioid misuse:
1)viral infection secondary to sharing needles: HIV, hepatitis B & C
2)bacterial infection secondary to injection: infective endocarditis, septic arthritis,
septicaemia, necrotising fasciitis
3)venous thromboembolism
4)overdose may lead to respiratory depression and death
5)psychological problems: craving
6)social problems: crime, prostitution, homelessness
Emergency management of opioid overdose:
3
-
8/18/2019 0014Clinical Pharmacology Notes 2015
37/84
• IV or IM naloxone: has a rapid onset and relatively short duration of action
Harm reduction interventions may include:
1)needle exchange
2)offering testing for HIV, hepatitis B & C
Management of opioid dependence
1)patients are usually managed by specialist drug dependence clinics although some GPs
with a specialist interest offer similar services
2)patients may be offered maintenance therapy or detoxification
3)NICE recommend methadone or buprenorphine as the first-line treatment in opioid
detoxification
4)compliance is monitored using urinalysis
5)detoxification should normally last up to 4 weeks in an inpatient/residential setting and up
to 12 weeks in the community
?ocaine:• Cocaine is an alkaloid derived from the coca plant.
• It is widely used as a recreational stimulant.
• The price of cocaine has fallen sharply in the past decade resulting in cocaine toxicity
becoming a much more frequent clinical problem.
• This increase has made cocaine a favourite topic of question writers.
Mechanism of action:
• cocaine blocks the uptake of dopamine, noradrenaline and serotonin
The use of cocaine is associated with a wide variety of adverse effects:
Cardiovascular effects:
1)myocardial infarction
2)both tachycardia and bradycardia may occur3)hypertension
4)QRS widening and QT prolongation
3
-
8/18/2019 0014Clinical Pharmacology Notes 2015
38/84
5)aortic dissection
Neurological effects:
1)seizures
2)mydriasis
3)hypertonia
4)hyperreflexia
Psychiatric effects:
1)agitation
2)psychosis
3)hallucinations
Others:1)hyperthermia
2)metabolic acidosis
3)rhabdomyolysis
Management of cocaine toxicity
1)in general benzodiazipines are generally first-line for most cocaine related problems
2)Chest pain: benzodiazipines + glyceryl trinitrate.
3)If myocardial infarction develops then primary percutaneous coronary intervention
4)hypertension: benzodiazipines + sodium nitroprusside
The use of beta-blockers in cocaine-induced cardiovascular problems is a controversial
issue.
The American Heart Association issued a statement in 2008 warning against the use of
beta-blockers (due to the risk of unopposed alpha-mediated coronary vasospasm) but
many cardiologists since have questioned whether this is valid. If a reasonable alternative
is given in an exam it is probably wise to choose it
.cstasy oisoning• Ecstasy (MDMA, 3, 4-Methylenedioxymethamphetamine)
• Its use became popular in the 1990's during the emergence of dance music culture
Clinical features:
1)neurological: agitation, anxiety, confusion, ataxia
3
-
8/18/2019 0014Clinical Pharmacology Notes 2015
39/84
-
8/18/2019 0014Clinical Pharmacology Notes 2015
40/84
• chronic alcohol consumption:
1)enhances GABA mediated inhibition in the CNS (similar to benzodiazepines) and
2)inhibits NMDA-type glutamate receptors
• alcohol withdrawal is thought to be lead to the opposite (decreased inhibitory GABA and
increased NMDA glutamate transmission)
Features:
• symptoms start at 6-12 hours
• peak incidence of seizures at 36 hours
• peak incidence of delirium tremens is at 72 hours
Management:
1)benzodiazepines
2)carbamazepine also effective in treatment of alcohol withdrawal
3)phenytoin is said not to be as effective in the treatment of alcohol withdrawal seizures
)lcohol > roblem drinking: managementNutritional support
•
SIGN recommends alcoholic patients should receive oral thiamine if their 'diet may bedeficient'
Drugs used
1)benzodiazepines for acute withdrawal
2)disulfram:
• Promotes abstinence
• alcohol intake causes severe reaction due to inhibition of acetaldehyde
dehydrogenase
• Patients should be aware that even small amounts of alcohol (e.g. In perfumes,
foods, mouthwashes) can produce severe symptoms.
• Contraindications include ischaemic heart disease and psychosis
3)acamprosate:
• reduces craving,• known to be a weak antagonist of NMDA receptors,
• improves abstinence in placebo controlled trials
40
-
8/18/2019 0014Clinical Pharmacology Notes 2015
41/84
.thylene glycol to9icityEthylene glycol is a type of alcohol used as a coolant or antifreeze
Features of toxicity are divided into 3 stages:
Stage 1: symptoms similar to alcohol intoxication: confusion, slurred speech, dizziness
Stage 2:
• metabolic acidosis with high anion gap and high osmolar gap
• Also tachycardia, hypertension
Stage 3: acute renal failure
Management has changed in recent times
1)Fomepizole,
• an inhibitor of alcohol dehydrogenase
• now used first-line in preference to ethanol
2)ethanol:• has been used for many years
• works by competing with ethylene glycol for the enzyme alcohol dehydrogenase
• this limits the formation of toxic metabolites (e.g. glycoaldehyde and glycolic acid)
which are responsible for the haemodynamic/metabolic features of poisoning
3)haemodialysis also has a role in refractory cases
Methanol oisoning• Methanol poisoning causes both:
1)the effects associated with alcohol (intoxication, nausea etc) and also
2)Specific visual problems, including blindness.
• These effects are thought to be secondary to the accumulation of formic acid.
• The actual pathophysiology of methanol-associated visual loss is not fully understood but
it is thought to be caused by a form of optic neuropathy
Management:1)fomepizole or
2)ethanol
41
-
8/18/2019 0014Clinical Pharmacology Notes 2015
42/84
-
8/18/2019 0014Clinical Pharmacology Notes 2015
43/84
-
8/18/2019 0014Clinical Pharmacology Notes 2015
44/84
-heohylline• Theophylline, like caffeine, is one of the naturally occurring methylxanthines.
• The main use of theophyllines in clinical medicine is as a bronchodilator in the
management of asthma and COPD
• The exact mechanism of action has yet to be discovered.
• One theory suggests theophyllines may be a non-specific inhibitor of phosphodiesteraseresulting in an increase in cAMP. Other proposed mechanisms include antagonism of
adenosine and prostaglandin inhibition
Theophylline poisoning
Features:
• acidosis, hypokalaemia
•
vomiting• tachycardia, arrhythmias
• seizures
Management:
• activated charcoal
• charcoal haemoperfusion is preferable to haemodialysis
Paracetamol o6erdose: risk *actorsThe following groups of patients are at an increased risk of developing hepatotoxicityfollowing a paracetamol overdose:
1)patients taking liver enzyme-inducing drugs (rifampicin, phenytoin, carbamazepine,
chronic alcohol excess, St John's Wort)
2)malnourished patients (e.g. anorexia or bulimia, cystic fibrosis, hepatitis C, alcoholism,
HIV
3)patients who have not eaten for a few days
44
-
8/18/2019 0014Clinical Pharmacology Notes 2015
45/84
Paracetamol o6erdose: metabolic athays1)The liver normally conjugates paracetamol with glucuronic acid/sulphate.
2)During an overdose the conjugation system becomes saturated leading to oxidation by
P450 mixed function oxidases*. This produces a toxic metabolite (N-acetyl-B-
benzoquinone imine)
3)Normally glutathione acts as a defence mechanism by conjugating with the toxin
forming the non-toxic mercapturic acid.
4)If glutathione stores run-out, the toxin forms covalent bonds with cell proteins,
denaturing them and leading to cell death.
5)This occurs not only in hepatocytes but also in the renal tubules
6)N-acetyl cysteine is used in the management of paracetamol overdose as it is a
precursor of glutathione and hence can increase hepatic glutathione production
*this explains why there is a lower threshold for treating patients who take P450
inducing medications e.g. phenytoin or rifampicin
,alicylate o6erdose• A key concept for the exam is to understand that salicylate overdose leads to a mixed
respiratory alkalosis and metabolic acidosis.
• Early stimulation of the respiratory centre leads to a respiratory alkalosis
• whilst later the direct acid effects of salicylates (combined with acute renal failure) may
lead to an acidosis
45
-
8/18/2019 0014Clinical Pharmacology Notes 2015
46/84
• In children metabolic acidosis tends to predominate
Features:
1)hyperventilation (centrally stimulates respiration)
2)tinnitus
3)lethargy
4)sweating, pyrexia*
5)nausea/vomiting
6)hyperglycaemia and hypoglycaemia
7)seizures
8)coma
Treatment:1)general (ABC, charcoal)
2)urinary alkalinization
3)haemodialysis
Indications for haemodialysis in salicylate overdose
1)serum concentration > 700mg/L
2)metabolic acidosis resistant to treatment
3)acute renal failure
4)pulmonary oedema
5)seizures
6)coma
*salicylates cause the uncoupling of oxidative phosphorylation leading to decreased
adenosine triphosphate production, increased oxygen consumption and increased carbon
dioxide and heat production
4
-
8/18/2019 0014Clinical Pharmacology Notes 2015
47/84
Mercury oisoningFeatures
1)paraesthesia
2)visual field defects
3)hearing loss
4)irritability
5)renal tubular acidosis
=ead oisoning• Along with acute intermittent porphyria, lead poisoning should be considered in questions
giving a combination of abdominal pain and neurological signs
Features:
1)abdominal pain
2)peripheral neuropathy (mainly motor)
3)fatigue
4)constipation
5)blue lines on gum margin (only 20% of adult patients, very rare in children)
Investigations:
1)The blood lead level is usually used for diagnosis. Levels greater than 10 mcg/dl are
considered significant
2)Full blood count: microcytic anaemia. Blood film shows red cell abnormalities including
basophilic stippling and clover-leaf morphology
3)raised serum and urine levels of delta aminolaevulinic acid may be seen making it
sometimes difficult to differentiate from acute intermittent porphyria4)urinary coproporphyrin is also increased (urinary porphobilinogen and uroporphyrin
levels are normal to slightly increased)
Management - various chelating agents are currently used:
1)dimercaptosuccinic acid (DMSA)
2)D-penicillamine
3)EDTA
4)dimercaprol
4
-
8/18/2019 0014Clinical Pharmacology Notes 2015
48/84
=ithium• Lithium is mood stabilising drug used most commonly prophylatically in bipolar disorder
but also as an adjunct in refractory depression.
• It has a very narrow therapeutic range (0.4-1.0 mmol/L) and a long plasma half-life being
excreted primarily by the kidneys.
Mechanism of action - not fully understood, two theories:
1)interferes with inositol triphosphate formation
2)interferes with cAMP formation
Adverse effects:
1)nausea/vomiting, diarrhoea
2)fine tremor
3)polyuria (secondary to nephrogenic diabetes insipidus)
4)thyroid enlargement, may lead to hypothyroidism
5)ECG: T wave flattening/inversion
6)weight gain
Monitoring of patients on lithium therapy:
1)Inadequate monitoring of patients taking lithium is common - NICE and the National
Patient Safety Agency (NPSA) have issued guidance to try and address this. As a result it
is often an exam hot topic
2)Lithium blood level should 'normally' be checked every 3 months. Levels should be taken
12 hours post-dose
3)thyroid and renal function should be checked every 6 months
4)patients should be issued with an information booklet, alert card and record book
4
-
8/18/2019 0014Clinical Pharmacology Notes 2015
49/84
=ithium to9icity• Lithium toxicity generally occurs following concentrations > 1.5 mmol/L.
• Toxicity may be precipitated by:
1)dehydration, diuretics (especially bendroflumethiazide)
2)renal failure,
3)ACE inhibitors4)Metronidazole
Features of toxicity
1)coarse tremor (a fine tremor is seen in therapeutic levels)
2)acute confusion
3)seizure
4)coma
Management:
1)mild-moderate toxicity may respond to volume resuscitation with normal saline
2)haemodialysis may be needed in severe toxicity
3)Sodium bicarbonate is sometimes used but there is limited evidence to support this. By
increasing the alkalinity of the urine it promotes lithium excretion
Methaemoglobinaemia• Methaemoglobinaemia describes haemoglobin which has been oxidised from Fe2+(ferrous
iron)to Fe3+(ferric iron).
• This is normally regulated by NADH methaemoglobin reductase, which transfers electrons
from NADH to methaemoglobin resulting in the reduction of methaemoglobin to
haemoglobin.
• There is tissue hypoxia as Fe3+ cannot bind oxygen, and hence the oxidation dissociation
curve is moved to the left
Congenital causes:
1)haemoglobin chain variants: HbM, HbH
2)NADH methaemoglobin reductase deficiency
Acquired causes:
1)drugs:
1.sulphonamides,
2.nitrates, , sodium nitroprusside,3.primaquine
4.dapsone
48
-
8/18/2019 0014Clinical Pharmacology Notes 2015
50/84
2)chemicals: aniline dyes
Features:
1)'chocolate' cyanosis
2)dyspnoea, anxiety, headache
3)severe: acidosis, arrhythmias, seizures, coma
4)normal pO2 but decreased oxygen saturation
Management:
1)NADH - methaemoglobinaemia reductase deficiency: ascorbic acid
2)IV methylene blue if acquired
?yanide oisoning• Cyanide may be used in insecticides, photograph development and the production of
certain metals.
• Toxicity results from reversibleinhibition of cellular oxidising enzymes
Presentation:
1)'classical' features: brick-red skin, smell of bitter almonds519: j,9:
2)acute: hypoxia, hypotension, headache, confusion
3)chronic: ataxia, peripheral neuropathy, dermatitis
Management:
1)supportive measures: 100% oxygen
50
-
8/18/2019 0014Clinical Pharmacology Notes 2015
51/84
2)definitive:
⇒ hydroxocobalamin (intravenously), also
⇒ combination of amyl nitrite (inhaled), sodium nitrite (intravenously), and sodium
thiosulfate (intravenously)
?arbon mono9ide oisoning• Carbon monoxide has high affinity for haemoglobin and myoglobin resulting in a left-shiftof the oxygen dissociation curve and tissue hypoxia.
• There are approximately 50 per year deaths from accidental carbon monoxide poisoning in
the UK
• Questions may hint at badly maintained housing e.g. student houses
Features of carbon monoxide toxicity :
1)headache: 90% of cases
2)nausea and vomiting: 50%
3)vertigo: 50%
4)confusion: 30%
5)subjective weakness: 20%
6)severe toxicity: 'pink' skin and mucosae, hyperpyrexia, arrhythmias, extrapyramidal
features, coma, death
Typical carboxyhaemoglobin levels
• < 3% non-smokers
• < 10% smokers
• 10 - 30% symptomatic: headache, vomiting
• > 30% severe toxicity
Management
• 100% oxygen
• hyperbaric oxygen
Indications for hyperbaric oxygen*1)loss of consciousness at any point
2)neurological signs other than headache
3)myocardial ischaemia or arrhythmia
4)pregnancy
*as stated in the 2008 Department of Health publication 'Recognising Carbon Monoxide
Poisoning'
Erganohoshate insecticide oisoning
51
-
8/18/2019 0014Clinical Pharmacology Notes 2015
52/84
One of the effects of organophosphate poisoning is inhibition of acetylcholinesterase
Features can be predicted by the accumulation of acetylcholine (mnemonic =SLUD)
• Salivation
• Lacrimation
• Urination
• Defecation/diarrhoea
• cardiovascular: hypotension, bradycardia
• also: small pupils, muscle fasciculation
Management:
• atropine
• the role of pralidoxime is still unclear - meta-analyses to date have failed to show anyclear benefit
52
-
8/18/2019 0014Clinical Pharmacology Notes 2015
53/84
aemodialysis in o6erdoseDrugs that can be cleared with haemodialysis - mnemonic: BLAST
1)Barbiturate2)Lithium
3)Alcohol (inc methanol, ethylene glycol)
4)Salicylates
5)Theophyllines (charcoal haemoperfusion is preferable)
Drugs which cannot be cleared with haemodialysis include
1)tricyclics2)benzodiazepines
3)dextropropoxyphene (Co-proxamol)
4)digoxin
5)beta-blockers
-heraeutic drug monitoring
Lithium• range = 0.4 - 1.0 mmol/l
• take 12 hrs post-dose
Digoxin
• at least 6 hrs post-dose
Phenytoin
• trough levels immediately before dose
Ciclosporin
• trough levels immediately before dose
53
-
8/18/2019 0014Clinical Pharmacology Notes 2015
54/84
-
8/18/2019 0014Clinical Pharmacology Notes 2015
55/84
rug causes o* urticariaThe following drugs commonly cause urticaria:
1)aspirin
2)penicillins
3)NSAIDs
4)opiates
rug>induced imaired glucose toleranceDrugs which are known to cause impaired glucose tolerance include:
1)thiazides, furosemide (less common)2)steroids
3)tacrolimus, ciclosporin
4)interferon-alpha
5)nicotinic acid
6)atypical antipsychotics e.g. olanzapine
Beta-blockers cause a slight impairment of glucose tolerance. They should also be used with
caution in diabetics as they can interfere with the metabolic and autonomic responses to
hypoglycaemia
rugs causing ocular roblemsCataracts
• steroids
Corneal opacities
1)amiodarone
55
-
8/18/2019 0014Clinical Pharmacology Notes 2015
56/84
-
8/18/2019 0014Clinical Pharmacology Notes 2015
57/84
3)anabolic steroids, testosterones
4)phenothiazines: chlorpromazine, prochlorperazine
5)sulphonylureas
6)fibrates
7)rare reported causes: nifedipine
Liver cirrhosis:
1)methotrexate
2)methyldopa
3)amiodarone
*risk may be reduced with erythromycin stearate
rug>induced ancytoaenia1)cytotoxics
2)antibiotics: trimethoprim, chloramphenicol
3)anti-rheumatoid: gold, penicillamine
4)carbimazole*
5)anti-epileptics: carbamazepine
6)sulphonylureas: tolbutamide
*causes both agranulocytosis and pancytopaenia
rug>induced thrombocytoenia (Probable immune mediated)
5
-
8/18/2019 0014Clinical Pharmacology Notes 2015
58/84
1)quinine
2)Abciximab
3)NSAIDS
4)diuretics: furosemide
5)antibiotics: penicillins, sulphonamides, rifampicin
6)anticonvulsants: carbamazepine, valproate
7)heparin
Osteoporosis management:
• NICE guidelines were updated in 2008 on the secondary prevention of osteoporotic fractures in
postmenopausal women.
• Key points include:
Treatment is indicated following osteoporotic fragility fractures in postmenopausal women
who are confirmed to have osteoporosis (a T-score of - 2.5 SD or below).
In women aged 75 years or older, a DEXA scan may not be required 'if the responsible
clinician considers it to be clinically inappropriate or unfeasible'
vitamin D and calcium supplementation should be offered to all women unless the clinician
is confident they have adequate calcium intake and are vitamin D replete
5
-
8/18/2019 0014Clinical Pharmacology Notes 2015
59/84
alendronate is first-line
Around 25% of patients cannot tolerate alendronate, usually due to upper gastrointestinal
problems. These patients should be offeredrisedronate oretidronate (see treatment
criteria below)
strontium ranelate andraloxifeneare recommended if patients cannot tolerate
bisphosphonates (see treatment criteria below)
Treatment criteria for patients not taking alendronate:
• Unfortunately, a number of complicated treatment cut-off tables have been produced in the
latest guidelines for patients who do not tolerate alendronate
• These take into account a patients age, their T-score and the number of risk factors they have
from the following list:
1)parental history of hip fracture
2)alcohol intake of 4 or more units per day
3)rheumatoid arthritis
The most important thing to remember is:
1)the T-score criteria for risedronate or etidronate are less than the others implying that
these are the second line drugs
2)if alendronate, risedronate or etidronate cannot be taken then strontium ranelate or
raloxifene may be given based on quite strict T-scores (e.g. a 60-year-old woman would
need a T-score < -3.5)
3)the strictest criteria are for denosumab
A Bisphosphonates:
1)alendronate, risedronate and etidronate are all licensed for the prevention and treatment
of post-menopausaland glucocorticoid-induced osteoporosis
2)all three have been shown toreduce the risk of both vertebral and non-vertebral
fractures although alendronate, risedronate may be superior to etidronate in preventing hip
fractures
3)ibandronate is aonce-monthly oral bisphosphonate
Vitamin D and calcium:
• poor evidence base to suggest reduced fracture rates in the general population at risk of
osteoporotic fractures - may reduce rates in frail, housebound patients
C)Raloxifene:
58
-
8/18/2019 0014Clinical Pharmacology Notes 2015
60/84
selective oestrogen receptor modulator (SERM)
• has been shown to prevent bone loss and toreduce the risk of vertebral fractures, but
hasnot yet been shown to reduce the risk of non-vertebral fractures
has been shown toincrease bone density in the spine and proximal femur
• may worsen menopausal symptoms
increased risk of thromboembolic events• maydecrease risk of breast cancer
D Strontium ranelate :
• dual action bone agent:
increases deposition of new bone by osteoblasts (promotes differentiation of pre-
osteoblast to osteoblast) and
reduces the resorption of bone by inhibiting osteoclasts
• Concerns regarding the safety profile of strontium have been raised recently.
• It should only be prescribed by a specialist in secondary care
due to these concerns the European Medicines Agency in 2014 said itshould only be
used by people for whom there are no other treatments for osteoporosis
Adverse Effects:
1) increased risk of cardiovascular events: any history of cardiovascular disease or
significant risk of cardiovascular disease is a contraindication2) increased risk of thromboembolic events:a Drug Safety Update in 2012 recommended it
is not used in patients with a history of venous thromboembolism
3) may cause serious skin reactions such asStevens Johnson syndrome
E) Denosumab:
human monoclonal antibody
• inhibits RANK ligand, which in turninhibits the maturation of osteoclasts
• given as asingle subcutaneous injection every 6 months
• initial trial data suggests that it is effective and well tolerated
Teriparatide:
recombinant form of parathyroid hormone
very effective at increasing bone mineral density butrole in the management of
osteoporosis yet to be clearly defined
z Hormone replacement therapy:
0
-
8/18/2019 0014Clinical Pharmacology Notes 2015
61/84
• has been shown toreduce the incidence of vertebral fracture and non-vertebral
fractures
• due to concerns aboutincreased rates of cardiovascular disease and breast cancer it is
no longer recommended for primary or secondary prevention of osteoporosis
unless the woman is suffering from vasomotor symptoms
{ Hip protectors:
• evidence to suggest significantly reduce hip fractures in nursing home patients
• compliance is a problem
I Falls risk assessment:
• no evidence to suggest reduced fracture rates
• however, do reduce rate of falls and should be considered in management of high risk
patients
;ishoshonates• Bisphosphonates are analogues of pyrophosphate, a molecule which decreases
demineralisation in bone.
• They inhibit osteoclasts by reducing recruitment and promoting apoptosis.
Clinical uses:
1)prevention and treatment of osteoporosis
2)hypercalcaemia
3)Paget's disease
4)pain from bone metatases
Adverse effects
1)oesophageal reactions: oesophagitis, oesophageal ulcers (especially alendronate)
2)osteonecrosis of the jaw
3)increased risk of atypical stress fractures of the proximal femoral shaft in patients
taking alendronate
The BNF suggests the following counselling for patients taking oral bisphosphonates• 'Tablets should be swallowed whole with plenty of water while sitting or standing; to be
given on an empty stomach at least 30 minutes before breakfast (or another oral
1
-
8/18/2019 0014Clinical Pharmacology Notes 2015
62/84
medication); patient should stand or sit upright for at least 30 minutes after taking
tablet'
PhenytoinPhenytoin is used to in the management of seizures.
Mechanism of action
• sodium channel blocker, decreasing the sodium influx into neurons which in turn
decreases excitability
Adverse effects:
Phenytoin is associated with a large number of adverse effects. These may be divided into
acute, chronic, idiosyncratic and teratogenic
Acute:
1)initially: dizziness, diplopia, nystagmus, slurred speech, ataxia
2)later: confusion, seizures
Chronic:
1)common:
1.gingival hyperplasia (secondary to increased expression of platelet derived
growth factor, PDGF),
2.hirsutism,
3.coarsening of facial features,
4.drowsiness2)megaloblastic anaemia (secondary to altered folate metabolism)
3)peripheral neuropathy
2
-
8/18/2019 0014Clinical Pharmacology Notes 2015
63/84
4)enhanced vitamin D metabolism causing osteomalacia
5)lymphadenopathy
6)dyskinesia
Idiosyncratic:
1)fever
2)rashes, including severe reactions such as toxic epidermal necrolysis
3)hepatitis
4)Dupuytren's contracture*
5)aplastic anaemia
6)drug-induced lupus
Teratogenic:• associated with cleft palate and congenital heart disease
*although not listed in the BNF
,odium 6alroateSodium valproate is used in the management of epilepsy and is first line therapy for
generalised seizures. It works by increasing GABA activity.
Adverse effects:1)gastrointestinal: nausea
2)increased appetite and weight gain
3)alopecia: regrowth may be curly
4)ataxia
5)tremor
6)hepatitis
7)pancreatitis
8)thromobcytopaenia
9)teratogenic
3
-
8/18/2019 0014Clinical Pharmacology Notes 2015
64/84
10) hyponatraemia
+ehrotic syndrome: causesPrimary glomerulonephritis accounts for around 80% of cases
• minimal change glomerulonephritis (causes 80% in children, 30% in adults)
• membranous glomerulonephritis
4
-
8/18/2019 0014Clinical Pharmacology Notes 2015
65/84
• focal segmental glomerulosclerosis
• membranoproliferative glomerulonephritis
Systemic disease (about 20%)
• diabetes mellitus
• systemic lupus erythematosus
• amyloidosis
Drugs
• gold (sodium aurothiomalate), penicillamine
Others
• congenital• neoplasia: carcinoma, lymphoma, leukaemia, myeloma
• infection: bacterial endocarditis, hepatitis B, malaria
Prescribing in atients ith renal *ailureQuestions regarding which drugs to avoid in renal failure are common
Drugs to avoid in renal failure:
1)antibiotics: tetracycline, nitrofurantoin
2)NSAIDs
3)lithium
4)metformin
Drugs likely to accumulate in chronic kidney disease - need dose adjustment
1)most antibiotics including penicillins, cephalosporins, vancomycin, gentamicin,
streptomycin2)digoxin, atenolol
3)methotrexate
4)sulphonylureas
5)furosemide
6)opioids
Drugs relatively safe - can sometimes use normal dose depending on the degree of chronickidney disease:
• antibiotics: erythromycin, rifampicin
5
-
8/18/2019 0014Clinical Pharmacology Notes 2015
66/84
-
8/18/2019 0014Clinical Pharmacology Notes 2015
67/84
,ildenaBlSildenafil is a phosphodiesterase type V inhibitor used in the treatment of impotence.
Contraindications:
1)patients taking nitrates and related drugs such as nicorandil
2)hypotension
3)recent stroke or myocardial infarction (NICE recommend waiting 6 months)
4)non-arteritic anterior ischaemic optic neuropathy
Side-effects:
1)visual disturbances e.g. blue discolouration, non-arteritic anterior ischaemic opticneuropathy
2)nasal congestion
3)flushing
4)gastrointestinal side-effects
5)headache
-
8/18/2019 0014Clinical Pharmacology Notes 2015
68/84
-
8/18/2019 0014Clinical Pharmacology Notes 2015
69/84
Prescribing in regnant atients• Very few drugs are known to be completely safe in pregnancy.
• Some countries have developed a grading system - see the link.
• The list below largely comprises of those known to be harmful:
Antibiotics
• tetracyclines
• aminoglycosides
• sulphonamides and trimethoprim
• quinolones: the BNF advises to avoid due to arthropathy in some animal studies
Other drugs• ACE inhibitors, angiotensin II receptor antagonists
• statins
• warfarin
• sulfonylureas
• retinoids (including topical)
• cytotoxic agents
The majority of antiepileptics including valproate, carbamazepine and phenytoin are known to
8
-
8/18/2019 0014Clinical Pharmacology Notes 2015
70/84
be potentially harmful. The decision to stop such treatments however is difficult as
uncontrolled epilepsy is also a risk
.clamsia• Eclampsia may be defined as the development of seizures in association pre-eclampsia.
• To recap, pre-eclampsia is defined as:
1)condition seen after 20 weeks gestation
2)pregnancy-induced hypertension
3)proteinuria
Magnesium sulphate is used to both prevent seizures in patients with severe pre-eclampsia
and treat seizures once they develop. Guidelines on its use suggest the following:
1)should be given once a decision to deliver has been made
2)in eclampsia an IV bolus of 4g over 5-10 minutes should be given followed by an
infusion of 1g / hour
3)urine output, reflexes, respiratory rate and oxygen saturations should be monitored
during treatment
4)treatment should continue for 24 hours after last seizure or delivery (around 40% of
seizures occur post-partum)
Other important aspects of treating severe pre-eclampsia/eclampsia include fluid restriction to
avoid the potentially serious consequences of fluid overload
;reast *eeding: contraindicationsThe major breastfeeding contraindications tested in exams relate to drugs (see below). Other
contraindications of note include:
1)galactosaemia
2)viral infections - this is controversial with respect to HIV in the developing world. This is
because there is such an increased infant mortality and morbidity associated with
bottle feeding that some doctors think the benefits outweigh the risk of HIV
transmission
Drug contraindications
The following drugs can be given to mothers who are breast feeding:
0
-
8/18/2019 0014Clinical Pharmacology Notes 2015
71/84
1)antibiotics: penicillins, cephalosporins, trimethoprim
2)endocrine: glucocorticoids (avoid high doses), levothyroxine*
3)epilepsy: sodium valproate, carbamazepine
4)asthma: salbutamol, theophyllines
5)psychiatric drugs: tricyclic antidepressants, antipsychotics**
6)hypertension: beta-blockers, hydralazine, methyldopa
7)anticoagulants: warfarin, heparin
8)digoxin
The following drugs should be avoided:
• antibiotics: ciprofloxacin, tetracycline, chloramphenicol, sulphonamides
• psychiatric drugs: lithium, benzodiazepines
•
aspirin• carbimazole
• sulphonylureas
• cytotoxic drugs
• amiodarone
*the BNF advises that the amount is too small to affect neonatal hypothyroidism screening
**clozapine should be avoided
ormone relacement theray: indicationsHormone replacement therapy (HRT) involves the use of a small dose of oestrogen,
combined with a progestogen (in women with a uterus), to help alleviate menopausal
1
-
8/18/2019 0014Clinical Pharmacology Notes 2015
72/84
symptoms.
The indications for HRT have changed significantly over the past ten years as the long-term
risks became apparent, primarily as a result of the Women's Health Initiative (WHI) study.
Indications:
1)vasomotor symptoms such as flushing, insomnia and headaches
2)premature menopause: should be continued until the age of 50 years
3)osteoporosis: but should only be used as second-line treatment
The main indication is the control of vasomotor symptoms. The other indications such as
reversal of vaginal atrophy and prevention of osteoporosis should be treated with other agents
as first-line therapies
Other benefits include a reduced incidence of colorectal cancer
?ombined oral contraceti6e ill: contraindicationsThe decision of whether to start a women on the combined oral contraceptive pill is now
guided by the UK Medical Eligibility Criteria (UKMEC). This scale categorises the potential
cautions and contraindications according to a four point scale, as detailed below:
UKMEC 1: a condition for which there is no restriction for the use of the contraceptive method
UKMEC 2: advantages generally outweigh the disadvantages
UKMEC 3: disadvantages generally outweigh the advantages
UKMEC 4: represents an unacceptable health risk
Examples of UKMEC 3 conditions include
1)more than 35 years old and smoking less than 15 cigarettes/day
2)BMI > 35 kg/m̂ 2*
3)migraine without aura and more than 35 years old
4)family history of thromboembolic disease in first degree relatives < 45 years
5)controlled hypertension
6)immobility e.g. wheel chair use
7)breast feeding 6 weeks - 6 months postpartum
Examples of UKMEC 4 conditions include
• more than 35 years old and smoking more than 15 cigarettes/day
• migraine with aura
• history of thromboembolic disease or thrombogenic mutation
• history of stroke or ischaemic heart disease
• breast feeding < 6 weeks post-partum
2
-
8/18/2019 0014Clinical Pharmacology Notes 2015
73/84
• uncontrolled hypertension
• breast cancer
• major surgery with prolonged immobilisation
Diabetes mellitus diagnosed > 20 years ago is classified as UKMEC 3 or 4 depending on
severity
*The UKMEC 4 rating for a BMI > 40 kg/m̂ 2 was removed in 2009.
Progestogen only ill:Advantages
• highly effective (failure rate = 1 per 100 woman years)
• doesn't interfere with sex
• contraceptive effects reversible upon stopping
• can be used whilst breast-feeding
• can be used in situations where the combined oral contraceptive pill is contraindicatede.g. in smokers > 35 years of age and women with a history of venous thromboembolic
disease
Disadvantages
1)Irregular periods: some users may not have periods whilst others may have irregular or light
periods. This is the most common adverse effect
2)Doesn’t protect against sexually transmitted infections.
3)increased incidence of functional ovarian cysts
4)Common side-effects include breast tenderness, weight gain, acne and headaches. These
symptoms generally subside after the first few months
-amo9i*en• Tamoxifen is a selective estrogen receptor modulator (SERM) which acts as an oestrogen
receptor antagonist and partial agonist.• It is used in the management of oestrogen receptor positive breast cancer
Adverse effects
• menstrual disturbance: vaginal bleeding, amenorrhoea
• hot flushes
• venous thromboembolism
•
endometrial cancer
Tamoxifen is typically used for 5 years following removal of the tumour.
3
-
8/18/2019 0014Clinical Pharmacology Notes 2015
74/84
Raloxifene is a pure oestrogen receptor antagonist, and carries a lower risk of endometrial
cancer
)ntibiotics: bactericidal 6sJ bacteriostaticBactericidal antibiotics:
1)penicillins
2)cephalosporins
3)aminoglycosides
4)nitrofurantoin
5)metronidazole
6)quinolones7)rifampicin
8)isoniazid
Bacteriostatic antibiotics
1)chloramphenicol
2)macrolides
3)sulphonamides4)tetracyclines
5)trimethoprim
)ntibiotics: mechanisms o* actionThe lists below summarise the site of action of the commonly used antibiotics
Inhibit cell wall formation:
1)penicillins
2)cephalosporins
4
-
8/18/2019 0014Clinical Pharmacology Notes 2015
75/84
Inhibit protein synthesis:
1)aminoglycosides (cause misreading of mRNA)
2)chloramphenicol
3)macrolides (e.g. erythromycin)
4)tetracyclines
5)fusidic acid
Inhibit DNA synthesis:
1)quinolones (e.g. ciprofloxacin)
2)metronidazole
3)sulphonamides
4)trimethoprim
Inhibit RNA synthesis
• rifampicin
Macrolides• Erythromycin was the first macrolide used clinically.
• Newer examples include clarithromycin and azithromycin.
• Macrolides act by inhibiting bacterial protein synthesis.
• If pushed to give an answer they are bacteriostatic in nature, but in reality this depends on
the dose and type of organism being treated.
Adverse effects:
1)Gastrointestinal side-effects are common. Nausea is less common with clarithromycin
than erythromycin
2)cholestatic jaundice: risk may be reduced if erythromycin stearate is used
3)P450 inhibitor (see below)
Common interactions:
5
-
8/18/2019 0014Clinical Pharmacology Notes 2015
76/84
Statins should be stopped whilst taking a course of macrolides:
⇒ Macrolides inhibit the cytochrome P450 isoenzyme CYP3A4 that metabolises
statins.
⇒ Taking macrolides concurrently with statins significantly increases the risk of
myopathy and rhabdomyolysis.
Kuinolones• Quinolones are a group of antibiotics which work by inhibiting DNA synthesis.
• They are bactericidal in nature. Examples include:
1)ciprofloxacin
2)levofloxacin
Mechanism of action:
• inhibit topoisomeras II (DNA gyrase) and topoisomerase IV
Adverse effects:
1)lower seizure threshold in patients with epilepsy
2)tendon damage (including rupture) - the risk is increased in patients also taking steroids
3)cartilage damage has been demonstrated in animal models and for this reason quinolones
are generally avoided (but not necessarily contraindicated) in children
Kuinuristin L dal*oristin antibiotics• injectable streptogrammin antibiotic
• combination of group A and group B streptogrammin
• inhibits bacterial protein synthesis by blocking tRNA complexes binding to the ribosome
Spectrum:
• most Gram positive bacteria
• exception: Enterococcus faecalis*
Adverse effects
1)thrombophlebitis (give via a central line)
2)arthralgia
3)P450 inhibitor
*not to be confused with Enterococcus faecium, which is sensitive to Quinupristin & dalfopristin
Antibiotic guidelines
The following is based on current BNF guidelines:
Respiratory system
-
8/18/2019 0014Clinical Pharmacology Notes 2015
77/84
Condition Recommended treatment
Exacerbations of chronic
bronchitis
Amoxicillin or tetracycline or clarithromycin
Uncomplicated
community-acquired
pneumonia
Amoxicillin (Doxycycline or clarithromycin in penicillin allergic,
add flucloxacillin if staphylococci suspected e.g. In influenza)
Pneumonia possibly
caused by atypical
pathogens
Clarithromycin
Hospital-acquired
pneumonia
Within 5 days of admission: co-amoxiclav or cefuroxime
More than 5 days after admission: piperacillin with tazobactam
OR a broad-spectrum cephalosporin (e.g. ceftazidime) OR a
quinolone (e.g. ciprofloxacin)
Urinary tract
Condition Recommended treatment
Lower urinary tractinfection
Trimethoprim or nitrofurantoin. Alternative: amoxicillin orcephalosporin
Acute pyelonephritis Broad-spectrum cephalosporin or quinolone
Acute prostatitis Quinolone or trimethoprim
Skin
Condition Recommended treatment
Impetigo Topical fusidic acid, oral flucloxacillin or erythromycin if widespread
Cellulitis Flucloxacillin
(clarithromycin or clindomycin if penicillin-allergic)
Erysipelas Phenoxymethylpenicillin (erythromycin if penicillin-allergic)
Animal or human bite Co-amoxiclav (doxycycline + metronidazole if penicillin-allergic)
Mastitis during Flucloxacillin
-
8/18/2019 0014Clinical Pharmacology Notes 2015
78/84
-
8/18/2019 0014Clinical Pharmacology Notes 2015
79/84
Condition Recommended treatment
Clostridium difficile First episode: metronidazole
Second or subsequent episode of infection: vancomycin
Campylobacter enteritis Clarithromycin
Salmonella (non-typhoid) Ciprofloxacin
Shigellosis Ciprofloxacin
*a combined topical antibiotic and corticosteroid is generally used for mild/moderate cases of
otitis externa
)nti6iral agentsDru lechanism o action Indications Adperse eectstoicity
Acicfopir • ˜uanosine analog’• phosphorylated by thymidine kinase
–hich in turn inhibits the viral ™šA polymerase
—ž’ ž›ž Crystalline nephropathy
zancicfopir • ˜uanosine analog’• phosphorylated by thymidine kinase
–hich in turn inhibits the viral ™šA polymerase
CMž Myelosuppressionagranulocytosis
|ibapirin • ˜uanosine analog• inhibits inosine monophosphate (IMP)
dehydrogenase’• interferes –ith the capping of viral
Mrna
Chronic hepatitisC’ Rž
—aemolytic anaemia
Amantadine • Inhibits uncoating (M< protein) of
virus in cellF• Also releases dopamine from nerve
endings
Influenza’Parkinson"sdisease
Confusion’ata%ia’slurred speech
}seftamipir Inhibits neuraminidase Influenza
oscarnet • Pyrophosphate analog –hich• inhibits viral ™šA polymerase
CMž’
—ž if notresponding to
šephroto%icity’
hypocalcaemia’hypomagnesaemia’
8
-
8/18/2019 0014Clinical Pharmacology Notes 2015
80/84
-
8/18/2019 0014Clinical Pharmacology Notes 2015
81/84
-
8/18/2019 0014Clinical Pharmacology Notes 2015
82/84
Mesna binds to these metabolites through its sulfhydryl-moieties and reduces the
incidence of haemorrhagic cystitis
2)myelosuppression
3)transitional cell carcinoma
Cytotoxic antibiotics
Cytotoxic Mechanism of action Adverse effects
Bleomycin Degrades preformed DNA Lung fibrosis
Doxorubicin • Stabilizes DNA-topoisomerase II complex
• inhibits DNA & RNA synthesis
Cardiomyopathy
Antimetabolites
Cytotoxic Mechanism of action Adverse effects
Methotrexate • Inhibits dihydrofolate reductase and
• thymidylate synthesis
1)Myelosuppression,
2)mucositis,
3)liver fibrosis,
4)lung fibrosis
Fluorouracil
(5-FU)
• Pyrimidine analogue
• inducing cell cycle arrest and apoptosis by blocking
thymidylatesynthase (works during S phase)
1)Myelosuppression,
2)mucositis,
3)dermatitis
6-
mercaptopurine
• Purine analogue
• activated by HGPRTase, decreasing purine
synthesis
Myelosuppression
Cytarabine • Pyrimidine antagonist.
• Interferes with DNA synthesis specifically at the S-
phase of the cell cycle and inhibits DNA polymerase
1)Myelosuppression,
2)ataxia
Acts on microtubules
2
-
8/18/2019 0014Clinical Pharmacology Notes 2015
83/84
Cytotoxic Mechanism of action Adverse effects
Vincristine,
vinblastine
Inhibits formation of microtubules Vincristine:
1)Peripheral neuropathy (reversible) ,
2)paralytic ileus
Vinblastine: myelosuppression
Docetaxel Prevents microtubule
depolymerisation & disassembly,
decreasing free tubulin
Neutropaenia
Other cytotoxic drugsCytotoxic Mechanism of action Adverse effects
Cisplatin Causes cross-linking in DNA 1)Ototoxicity,
2)peripheral neuropathy,
3)hypomagnesaemia
Hydroxyurea
(hydroxycarbamide)
Inhibits ribonucleotide reductase,
decreasing DNA synthesis
Myelosuppression
3
-
8/18/2019 0014Clinical Pharmacology Notes 2015
84/84